Abraxane nab-paclitaxel: Phase III started

Celgene disclosed in its 1Q14 earnings that it began an open-label Phase III trial to compare 100 mg/m 2 IV Abraxane on days 1 and 8 of a 21-day cycle plus best supportive care (BSC) vs. BSC alone following induction therapy with Abraxane and carboplatin in about 260 patients. Patients who achieve a complete response, partial response or stable disease after 4 cycles of Abraxane and carboplatin in the induction phase will continue to the maintenance phase. ...